Gallic Acid: A Potent Metabolite Targeting Shikimate Kinase in Acinetobacter baumannii
2024

Gallic Acid as a Potential Treatment for Acinetobacter baumannii Infections

publication 10 minutes Evidence: moderate

Author Information

Author(s): Alturki Mansour S., Al Khzem Abdulaziz H., Gomaa Mohamed S., Tawfeeq Nada, Alhamadah Marwah H., Alshehri Futun M., Alzahrani Raghad, Alghamdi Hanin, Rants’o Thankhoe A., Al Mouslem Abdulaziz K., Almaghrabi Mohammed, Calado Cecília R.C.

Primary Institution: Imam Abdulrahman Bin Faisal University

Hypothesis

Can gallic acid be repurposed as a selective inhibitor of shikimate kinase in Acinetobacter baumannii?

Conclusion

Gallic acid shows promising antibacterial activity against Acinetobacter baumannii and Enterococcus faecalis, making it a potential therapeutic candidate.

Supporting Evidence

  • Gallic acid showed very good activity against Acinetobacter baumannii and Enterococcus faecalis in the MIC and MBC assay.
  • Gallic acid exhibited better activity against Acinetobacter baumannii due to the overexpression of shikimate kinase.
  • The study provides a comprehensive computational and experimental framework for accelerating antimicrobial drug discovery.

Takeaway

Gallic acid, a natural compound, can help fight a superbug called Acinetobacter baumannii by blocking a key enzyme it needs to survive.

Methodology

The study used computational methods like molecular docking and dynamics simulations, followed by experimental validation through MIC and MBC assays.

Limitations

The study lacks in vivo confirmation of findings and does not account for potential resistance development in Acinetobacter baumannii.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/metabo14120727

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication